Inclusion Criteria:

- Histologically or cytologically confirmed diagnosis of metastatic, advanced, or
recurrent platinum-resistant epithelial ovarian, primary peritoneal or fallopian tube
cancer.

- Prior first line therapy with a platinum and taxane based combination as adjuvant
therapy

- Measurable disease defined by RECIST criteria

- Voluntary written informed consent before performance of any study-related procedure
not part of normal medical care, with the understanding that consent may be withdrawn
by the subject at any time without prejudice to future medical care.

- Female subject is either post-menopausal or surgically sterilized or willing to use
an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine
device, diaphragm with spermicide, condom with spermicide, or abstinence) for the
duration of the study.

- age > 18

- Karnofsky performance status > 70

- Up to three prior lines of cytotoxic therapy in the setting of recurrent disease.

- Estimated life expectancy of at least 3 months

- Women of child-bearing potential must have a negative pregnancy test

- Adequate hematopoietic function defined as:

- ANC ≥ 1500/mm3

- Platelets ≥ 100,000/mm3

- Hemoglobin ≥ 9 g/dL

- Magnesium ≥ lower limit of normal

- Calcium ≥ lower limit of normal

- Adequate renal and hepatic function defined as:

- Bilirubin ≤ 1.5 times upper limit of normal (ULN)

- SGOT ≤ 3 times ULN

- Alanine aminotransferase (ALT) ≤3xULN (if liver metastases ≤5xULN)

- Alkaline phosphatase ≤ 3 times ULN

- Creatinine ≤ 1.5 mg/dL times ULN

- Creatinine clearance ≤ 50 mL/min

Exclusion Criteria:

- Prior anti-EGFr antibody therapy (e.g., cetuximab) or treatment with small molecule
EGFr inhibitors (e.g., gefitinib, erlotinib, lapatinib)

- Prior treatment with gemcitabine

- Radiotherapy ≤ 14 days prior to enrollment.

- More than three lines of systemic chemotherapy for recurrent or advanced disease.
Prior hormonal therapy is allowed.

- Prior immunotherapy, or experimental or approved proteins/antibodies

- Female subject is pregnant or breast-feeding.

- Patient has received other investigational drugs within 28 days before enrollment

- Serious medical or psychiatric illness likely to interfere with participation in this
clinical study.

- Prior treatment with panitumumab

- Concurrent uncontrolled illness

- Ongoing or active infection

- History or active secondary cancer within the last 5 years, except for superficial
basal cell skin cancers, curatively resected non-melanoma skin cancer

- Psychiatric illness or social situation that would preclude study compliance.

- History or known presence of central nervous system (CNS) metastasis

- Subjects requiring chronic use of immunosuppressive agents (e.g., methotrexate,
cyclosporine)

- Clinically significant cardiovascular disease (including myocardial infarction,
unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac
arrhythmia) < 1 year before randomization

- History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or any
evidence of interstitial lung disease on baseline chest CT scan

- Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus,
acute or chronic active hepatitis B infection

- Major surgery within 28 days or minor surgery within 14 days of study enrollment